Page last updated: 2024-11-04

foscarnet

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Foscarnet is an antiviral medication used to treat cytomegalovirus (CMV) retinitis in people with AIDS, and to treat herpes simplex virus (HSV) infections in people with weakened immune systems. It is a pyrophosphate analogue that inhibits viral DNA polymerase. Foscarnet is administered intravenously and has a number of side effects, including nephrotoxicity, hypocalcemia, and hypomagnesemia. It is also used to treat acyclovir-resistant HSV infections. Foscarnet is not a cure for CMV or HSV, but it can help to control the infection and prevent serious complications. Foscarnet is an important antiviral medication because it is effective against a wide range of viruses, including those that are resistant to other antiviral medications. It is also studied for its potential to treat other viral infections, such as influenza and hepatitis C.'

Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3415
CHEMBL ID666
CHEBI ID127780
SCHEMBL ID23633
MeSH IDM0026166

Synonyms (65)

Synonym
DIVK1C_000915
KBIO1_000915
msl & pfa
dihydroxyphosphinecarboxylic acid oxide and msl, neutralizing monoclonal antibody
SPECTRUM_001359
nsc313410
IDI1_000915
dihydroxyphosphinecarboxylic acid oxide
phosphonoformic acid
pfa & rifn.alpha.a
phosphonoformate(trisodium) & recombinant alpha-a interferon
phosphonoformic acid & ifn-.alpha.
foscarnet & ifn-.alpha.
4428-95-9
foscarmet
foscarnet
C06456
carboxyphosphonic acid
1NKI
DB00529
phosphonomethanoic acid
phosphinecarboxylic acid, dihydroxy-, oxide
formic acid, phosphono-
phgosphonocarboxylic acid
KBIOGR_001419
KBIO2_004407
KBIO2_006975
KBIOSS_001839
KBIO2_001839
KBIO3_002567
SPECTRUM4_000840
SPECTRUM2_000668
SPBIO_000735
SPECTRUM3_001484
NINDS_000915
SPECTRUM5_000932
BSPBIO_003067
CHEBI:127780 ,
dihydroxyphosphanecarboxylic acid oxide
CHEMBL666 ,
j05ad01
bdbm50011181
dihydroxyphosphinecarboxylic acid oxide(pfa)
(pfa)dihydroxyphosphinecarboxylic acid oxide
phosphonoformic acid(pfa)
forscarnet
foscarnet (pfa)
phosphono-formic acid(pfa)
AKOS006281397
phosphonocarboxylic acid
unii-364p9rvw4x
364p9rvw4x ,
hsdb 8122
foscarnet [who-dd]
foscarnet [vandf]
gtpl5497
SCHEMBL23633
hydroxycarbonylphosphonic acid
ZJAOAACCNHFJAH-UHFFFAOYSA-N
DTXSID0048478 ,
Q420387
6-(2-nitrophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole
EN300-708767
phosphonoformic acid trisodium salt hexa
dtxcid0028452

Research Excerpts

Overview

Foscarnet sodium is an antiviral drug for the treatment of CMV retinitis, currently in the form of twice-weekly intravitreal injection. It is also an effective treatment in HHV-7 associated myelitis.

ExcerptReferenceRelevance
"Foscarnet is an important drug for the treatment of cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation (HSCT). "( Long-term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study.
Hino, M; Inose, R; Nagayama, K; Nanno, S; Sugimoto, T; Takahashi, K; Takahashi, M, 2022
)
2.5
"Foscarnet sodium is an antiviral drug for the treatment of CMV retinitis, currently in the form of twice-weekly intravitreal injection. "( Foscarnet calcium microcrystals as the intravitreal drug depot.
Cao, Q; Huang, Y; Sun, Y; Tao, Y, 2017
)
3.34
"Foscarnet is an effective treatment in HHV-7 associated myelitis."( Acute myelitis by human herpes virus 7 in an HIV-infected patient.
Buisán Catevilla, J; Corral, I; Escobar-Villalba, A; Galán, JC; Martínez Ulloa, PL; Monreal Laguillo, E; Pérez Torre, P; Rodríguez-Domínguez, M; Sainz de la Maza, S, 2016
)
1.16
"Foscarnet is a main treatment for disseminated cytomegalovirus infection in immunocompromised patients. "( Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature.
Rabinowicz, S; Somech, R; Yeshayahu, Y, 2017
)
3.34
"Foscarnet is a reasonable first line anti CMV agent in this setting."( CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature.
Chajek-Shaul, T; Hershcovici, T; Koslowsky, B; Wolf, D; Yaari, S, 2010
)
1.35
"Foscarnet is an active agent against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT), as well as ganciclovir. "( Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor.
Asakura, M; Atsuta, Y; Etoh, T; Fukuda, T; Hatanaka, K; Ikegame, K; Kanamori, H; Mori, T; Ogawa, H; Sakamaki, H; Suzuki, R; Takami, A; Taniguchi, S; Yoshida, T; Yoshihara, S; Yujiri, T, 2010
)
2.26
"Foscarnet (FOS) is a pyrophosphate analogue that inhibits both cytomegalovirus (CMV) and human immunodeficiency virus (HIV) replication. "( Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Agut, H; Boutolleau, D; Burrel, S; Canestri, A; Clavel-Osorio, C; Katlama, C; Marcelin, AG; Seang, S; Wirden, M, 2012
)
2.08
"Foscarnet is a suitable option as both pre-emptive therapy or for the treatment of active disease in these patients."( Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
Bacigalupo, A; Boyd, A; Clissold, S; Curtis, J; Slipper, J, 2012
)
2.54
"Foscarnet is a broad-spectrum viral DNA polymerase inhibitor active in vitro and in vivo against human immunodeficiency virus type 1 (HIV-1). "( Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.
Bazmi, H; Birch, C; Deacon, NJ; Gurusinghe, AD; Hooker, DJ; Mellors, J; Mills, J; Tachedjian, G, 1995
)
2.06
"Foscarnet is a synthetic antiviral agent with activity against herpesviruses and HIV. "( Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.
Fan-Harvard, P; Moser, EM; Oh, J; Sanchorawala, V; Smith, SP,
)
1.91
"Foscarnet is a pyrophosphate analogue that possesses substantial activity against human cytomegalovirus (HCMV) in patients with CMV retinitis. "( In vitro anti-human cytomegalovirus activity of liposome-encapsulated foscarnet.
Cinatl, J; Doerr, HW; Gümbel, HO; Ohrloff, C; Rabenau, H; Rückert, DG, 1994
)
1.97
"Foscarnet is an antiviral agent used for the treatment of cytomegalovirus retinitis and acyclovir-resistant herpes simplex virus infections in AIDS patients. "( Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro.
Cui, X; Drusano, GL; Trifillis, AL, 1993
)
1.97
"Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir."( Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
Andersson, B; Champlin, R; Gajewski, J; Giralt, S; Ippoliti, C; Khouri, I; Mehra, R; Morgan, A; Przepiorka, D; van Besien, K; Warkentin, D, 1997
)
2.46
"Foscarnet is an RT inhibitor that is a product analogue, in contrast to the widely used nucleoside analogues."( Pronounced anti-HIV-1 activity of foscarnet in patients without cytomegalovirus infection.
Bergdahl, S; Jacobsson, B; Moberg, L; Sönnerborg, A, 1998
)
1.3
"Foscarnet (PFA) is a pyrophosphate analogue antiviral active against human immunodeficiency virus (HIV-1) and herpesviruses. "( Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1.
Bazmi, H; Mellors, JW; Mills, J; Tachedjian, G, 1998
)
2.07
"Foscarnet is an antiviral agent commonly used for managing patients with cytomegalovirus infection. "( Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations.
Aweeka, FT; Gambertoglio, JG; Hedman, A; Jacobson, MA; Martin-Munley, S; Omachi, R; Schoenfeld, P; Tsunoda, S, 1999
)
2.01
"Foscarnet is an antiviral agent used to treat cytomegalovirus infection in AIDS patients and in transplant recipients. "( Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection.
Assem, M; Justrabo, E; Martin, L; Maurice-Estepa, L; Mousson, C; Rifle, G; Tanter, Y; Zanetta, G, 1999
)
1.97
"Foscarnet is an antiviral agent widely used in the treatment of cytomegalovirus (CMV) infection. "( Removal of Foscarnet by hemodialysis using dialysate-side values.
Gambertoglio, JG; Ing, TS; Leehey, DJ; Patel, SB; Popli, A; Sam, R, 2000
)
2.14
"Foscarnet is a non-thymidine kinase-dependent agent, but the emergence of ACV and foscarnet-resistant HSV requires a new therapeutic approach."( Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant.
Blot, N; Dehesdin, D; Janvresse, C; Schneider, P; Tron, P; Vannier, JP; Young, P, 2000
)
1.32
"Foscarnet is a pyrophosphate analog that directly inhibits viral DNA polymerase."( [In vitro susceptibility to ganciclovir and foscarnet of cytomegaloviruses].
Herrero, M; Labeaga, R; Margall, R; Muñoz, JM; Otegui, M; Prats, G; Rabella, N, 2001
)
1.29
"Foscarnet is a pyrophosphate analogue with activity against herpesviruses, human immunodeficiency virus (HIV), and other RNA and DNA viruses. "( Mechanism of action of foscarnet against viral polymerases.
Crumpacker, CS, 1992
)
2.04
"Foscarnet (Foscavir) is an antiviral drug for intravenous (i.v.) treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. "( Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs.
Lundström, J; Nordgren, T; Ryrfeldt, A, 1992
)
2.03
"Foscarnet is a potentially effective and tolerable antiviral agent for patients with acyclovir-resistant, varicella-zoster virus infection; however, the optimal dosage and duration of therapy require further study, as does the relation between clinical findings and in-vitro susceptibility results."( Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection.
Berger, TG; Biron, KK; Gilson, I; Mills, J; Safrin, S; Wofsy, CB; Wolfe, PR, 1991
)
3.17
"Foscarnet is an effective therapy for CMV disease of the gastrointestinal tract, with rapid resolution of clinical symptoms, long-term remission of esophageal disease, and shorter disease-free periods for CMV colitis."( Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome.
Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991
)
2.45
"Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. "( Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991
)
2.11
"Foscarnet is an attractive anti-CMV drug but must be given parenterally and is completely dependent on renal clearance for elimination."( Management of cytomegalovirus disease with antiviral drugs.
Balfour, HH,
)
0.85
"Foscarnet is a pyrophosphate analogue that has been successfully used in severe cytomegalovirus (CMV) infections. "( Foscarnet nephrotoxicity: mechanism, incidence and prevention.
Baumelou, A; Beaufils, H; Danis, M; Deray, G; Dohin, E; Gentilini, M; Katlama, C; Levaltier, B; Martinez, F; Rozenheim, M, 1989
)
3.16
"Foscarnet (FC) is a new antiviral agent which has been recently proposed for the treatment of severe cytomegalovirus (CMV) infections in immunocompromised patients. "( Acute renal failure induced by foscarnet: 4 cases.
Baumelou, A; Cacoub, P; Deray, G; Gentilini, M; Jacobs, C; Le Hoang, P; Rousselie, R; Rozenbaum, W; Soubrie, C, 1988
)
2

Effects

Foscarnet has been used successfully in the treatment of limited numbers of immunocompromised patients with CMV-associated gastrointestinal and other infections. It has similar efficacy to ganciclovir but a different side effect profile, is more difficult to administer and less well-tolerated.

ExcerptReferenceRelevance
"Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes."( Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Jacobson, MA; O'Donnell, JJ, 1991
)
1.23
"Foscarnet has previously been shown to inhibit influenza RNA polymerase activity. "( Mode of interference of trisodium phosphonoformate (INN: foscarnet sodium), with influenza virus mRNA synthesis.
Datema, R; Stridh, S, 1984
)
1.96
"Foscarnet has been used successfully in the treatment of limited numbers of immunocompromised patients with CMV-associated gastrointestinal (improvement in over 67% of patients) and other infections."( Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Bryson, HM; Wagstaff, AJ, 1994
)
2.45
"Foscarnet has been demonstrated to delay the progression of CMV retinitis and is an alternative to ganciclovir."( Intravenous foscarnet administration for treatment of cytomegalovirus retinitis.
Greening, JG,
)
1.23
"Foscarnet treatment has been used with some clinical benefit in patients with acyclovir-resistant HSV or VZV, or ganciclovir-resistant CMV."( Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options.
Reusser, P, 1996
)
1.02
"Foscarnet, which has similar efficacy to ganciclovir but a different side effect profile, is more difficult to administer and is less well-tolerated."( Therapeutic developments in cytomegalovirus retinitis.
Hoffman, VF; Skiest, DJ, 2000
)
1.03
"Foscarnet has also been shown to be effective as preemptive therapy for CMV in allogenic stem cell transplant patients and as therapy for aciclovir-resistant HSV infections."( Prophylaxis against herpesvirus infections in transplant recipients.
Ljungman, P, 2001
)
1.03
"Foscarnet has been shown to inhibit the proliferation of human T and B lymphocytes in vitro. "( Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response?
Hansson, BG; Nordenfelt, E; Riesbeck, K; Weiland, O, 1991
)
1.72
"Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes."( Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Jacobson, MA; O'Donnell, JJ, 1991
)
1.23
"Foscarnet has been shown to be active in vitro against the human immunodeficiency virus and all human herpesviruses including cytomegalovirus (CMV). "( Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989
)
1.96

Actions

Foscarnet did not inhibit the calcium influx component of the noradrenaline contraction, nor did it affect the inhibition of this component by the L-type calcium channel antagonists verapamil and nicardipine.

ExcerptReferenceRelevance
"Foscarnet did not inhibit the calcium influx component of the noradrenaline contraction, nor did it affect the inhibition of this component by the L-type calcium channel antagonists verapamil and nicardipine."( Foscarnet inhibits vascular smooth muscle contraction.
Leaver, DD; Mai, X; Paspaliaris, V, 1993
)
2.45
"Foscarnet is shown to inhibit influenza A virus replication by inhibiting viral RNA synthesis in infected cells. "( Comparison of foscarnet and foscarnet esters as anti-influenza virus agents.
Datema, R; Ekström, C; Strid, S, 1989
)
2.08

Treatment

Treatment with foscarnet, an inhibitor of viral-DNA polymerase, in three patients with EBV-associated post-transplant lymphoproliferative disease (PTLD) after heart/kidney transplantation resulted in complete remission. Treatment was not associated with any significant side effects.

ExcerptReferenceRelevance
"Foscarnet treatment was initiated in place of acyclovir and his consciousness improved, with a slight improvement in visual acuity."( Acyclovir resistant acute herpes simplex encephalitis associated with acute retinal necrosis: A case report and review of the literature.
Aoki, M; Fukae, J; Kimura, S; Nabeshima, K; Ogura, H; Tsuboi, Y, 2017
)
1.18
"Foscarnet is a main treatment for disseminated cytomegalovirus infection in immunocompromised patients. "( Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature.
Rabinowicz, S; Somech, R; Yeshayahu, Y, 2017
)
3.34
"Foscarnet treatment resulted both in viral load decline and disappearance of HHV-6-related bone marrow suppression and predisposition to severe infections."( Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet.
Dimitroulia, E; Lagadinou, ED; Liga, M; Marangos, M; Panos, G; Spyridonidis, A; Tiniakou, M; Tsakris, A; Tzouvara, E; Zoumbos, N, 2010
)
1.27
"Foscarnet treatment rapidly and safely eradicated CMV DNAemia, and also patients who only reduced the immunosuppression and continued on VGCV treatment eventually cleared the virus."( Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Asberg, A; Hartmann, A; Haug Dorenberg, D; Kristiansen, KI; Leivestad, T; Myhre, HA; Rollag, H, 2011
)
1.09
"Foscarnet induction treatment is highly effective in suppressing or reducing DNA levels in both blood leukocytes and aqueous humor."( Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group.
Baldanti, F; Furione, M; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zella, D; Zipeto, D, 1994
)
1.41
"Foscarnet treatment has been used with some clinical benefit in patients with acyclovir-resistant HSV or VZV, or ganciclovir-resistant CMV."( Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options.
Reusser, P, 1996
)
1.02
"Foscarnet, an expensive treatment, has serious side effects, especially kidney toxicity."( Kaposi's sarcoma: possible Foscarnet treatment?
James, JS, 1995
)
1.31
"Foscarnet-treated patients had a reduced duration of shedding of virus, and this was significant for men."( Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.
Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987
)
1.23
"Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1.7 days) than placebo (3.4 days) treated men (p less than 0.02)."( Topical treatment of recurrent genital herpes infections with foscarnet.
Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985
)
1.23
"Treatment with foscarnet was effective in achieving improvement of symptoms and clearance of HHV-7 DNA in CSF in the cases of encephalitis and myelitis, while ganciclovir was ineffective in the case of encephalitis."( Molecular detection of human herpesvirus 7 DNA in cerebrospinal fluid from adult patients with neurological disorders.
Corral, Í; Galán, JC; Kawiorski, MM; López-Martínez, MJ; Rodríguez, M; Sainz de la Maza, S, 2018
)
0.82
"Treatment with foscarnet sodium and hypertonic saline was started with improvement of neurological condition within several days."( Severe hyponatremia caused by syndrome of inappropriate secretion of antidiuretic hormone developed as initial manifestation of human herpesvirus-6-associated acute limbic encephalitis after unrelated bone marrow transplantation.
Abe, D; Iseki, T; Kawaguchi, T; Kawajiri, C; Nagao, Y; Nakaseko, C; Ohwada, C; Sakai, S; Sakaida, E; Shimizu, N; Sugita, Y; Takeda, Y; Takeuchi, M; Tsukamoto, S; Yamazaki, A; Yokote, K, 2013
)
0.73
"Treatment with foscarnet, an inhibitor of viral-DNA polymerase, in three patients with EBV-associated post-transplant lymphoproliferative disease (PTLD) after heart (n = 2) and heart/kidney transplantation (n = 1), who did not respond to, or were not eligible for reduction of immunosuppression, resulted in complete remission (48+, 27 and 15 months respectively)."( Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease.
Anagnostopoulos, I; Hummel, MW; Jonas, S; Oertel, SH; Riess, HB, 2002
)
0.65
"A treatment with foscarnet was administered and clinical improvement was observed as early as the fourth day, with complete reepithelialization 50 days later."( [Chronic herpes resistant to acyclovir in a patient with AIDS].
About, I; Bernard, P; Capdeville, J; Massip, P, 1994
)
0.62
"Treatment with foscarnet significantly reduced the mean lesion area (49 versus 81 mm2; P = 0.01), the maximum lesion area (80 versus 141 mm2; P = 0.01), and the time to healing (P = 0.03) of the delayed classic lesions (n = 78)."( Effect of foscarnet cream on experimental UV radiation-induced herpes labialis.
Bernstein, DI; Blumberg, DA; Broberg, P; Bryson, Y; Evans, TG; Grafford, K; Martin-Munley, S; Schleupner, CJ; Spruance, SL, 1997
)
1.04
"Treatment with foscarnet cream was not associated with any significant side effects."( Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes.
Doraisingham, S; Lee, CT; Lim, KB; Ling, AE; Tan, T; Thirumoorthy, T, 1986
)
2.05
"Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection."( Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate).
Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987
)
0.81

Toxicity

Foscarnet was well tolerated without serious hematotoxicity and was not discontinued due to adverse events in any patient. Renal function normalized in all three, and no adverse sequelae were observed at 1 year of follow-up.

ExcerptReferenceRelevance
" No significant difference in the incidence of local or systemic adverse effects was noted between the two groups."( Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.
Aoki, FY; Lawee, D; Portnoy, J; Rosenthal, D, 1988
)
0.59
" Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only."( Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
Ahlmén, J; Klintmalm, G; Lernestedt, JO; Lönnqvist, B; Paulin, T; Ringdén, O; Wahren, B, 1986
)
0.51
" This study compared the morbidity and toxic reactions reported during the trial."( Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
, 1995
)
0.53
"001), and most of this excess was attributable to toxic reactions."( Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
, 1995
)
0.53
"Compared with ganciclovir, the use of foscarnet was more frequently limited by the occurrence of toxic reactions."( Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
, 1995
)
0.81
" Their adverse effects mostly involve bone marrow depression (e."( Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris, DJ, 1994
)
0.29
" Renal function normalized in all three, and no adverse sequelae due to foscarnet were observed at 1 year of follow-up."( A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet.
Koenig, S; Polis, MA; Seidel, EA, 1993
)
0.74
" Slit-lamp biomicroscopy revealed no toxic effects for any of the treated eyes."( Ocular toxicity of iontophoretic foscarnet in rabbits.
Equi, RA; Lee, DA; Sarraf, DA; Verdon, W; Yoshizumi, MO, 1995
)
0.57
" Surprisingly, AZT significantly increased serum creatinine levels on Days 5 and 11 of treatment (up to 40% increase), whereas PFA was less toxic (only approximately 17% increase on Day 5 of treatment)."( In vivo toxicity of foscarnet and zidovudine given alone or in combination.
Beauchamp, D; Bergeron, MG; Désormeaux, A; Gourde, P; Omar, RF; Tremblay, M, 1996
)
0.62
" Adverse events resulted in discontinuance of medication in the case of one patient."( Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.
Dieterich, DT; Faust, MJ; Johnson, J; Lew, EA; Martin-Munley, S; Nix, D; Poles, MA, 1997
)
0.53
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Foscarnet was well tolerated without serious hematotoxicity and was not discontinued due to adverse events in any patient."( Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation.
Asakura, H; Ito, S; Mochizuki, K; Nakao, S; Okumura, H; Sugimori, C; Takami, A; Yamashita, T,
)
1.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Grade 3 or greater adverse events occurred in 9 of the 10 prophylactic PFA patients and in 7 of the 10 control patients who had clinical backgrounds similar to the study subjects and underwent SCT during the same period."( Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation.
Hosokawa, K; Ishiyama, K; Katagiri, T; Kondo, Y; Nakao, S; Ohata, K; Takami, A; Yamazaki, H, 2012
)
0.65
"Although mortality was high in this population, foscarnet use, with proper precautions, was generally safe and significant renal dysfunction was lower than previously reported in other sources, even with extended use."( Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study.
Allen, A; Ison, MG; Lacloche, L; Pierce, B; Richardson, CL, 2018
)
1.05
" However, it is unknown whether aerosolized pentamidine has a similar adverse interaction with foscarnet."( Safety profile of the concomitant use of foscarnet and aerosolized pentamidine in allogeneic hematopoietic stem cell transplantation recipients.
Hino, M; Inose, R; Koh, H; Nagayama, K; Sugimoto, T; Takahashi, K; Takahashi, M, 2020
)
1.04

Pharmacokinetics

The ocular pharmacokinetics of foscarnet determined by noncompartmental analysis showed a 34-hour terminal elimination half-life and an apparent volume of distribution of 1. The results suggest that the intravitreal administration of ganciclovir has a better pharmacokinetic profile than foscarne.

ExcerptReferenceRelevance
" Pharmacokinetic parameters remained stable throughout the study."( Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.
Blanshard, C; Dohin, E; Frostegard, C; Gazzard, BG; Gazzard, D; Katlama, C; Singlas, E; Taburet, AM; Zorza, G, 1992
)
0.61
"Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy."( Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
Aweeka, FT; Gambertoglio, JG; Jacobson, MA; Raasch, R; van der Horst, C, 1992
)
1.98
" Pharmacokinetic properties of PFA in young (growing) and adult specific-pathogen-free cats were compared."( Age-related differences in pharmacokinetics of phosphonoformate in cats.
Mathes, LE; Michael, DF; Polas, PJ; Sams, RA; Swenson, CL, 1990
)
0.28
" A pharmacokinetic study was carried out as part of a clinical trial designed to evaluate the safety and efficacy of intermittently administered intravenous foscarnet for the treatment of CMV retinitis."( Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989
)
0.72
" For both regimens, serial blood sampling for pharmacokinetic analysis was performed for each drug alone (day 1 or 2) and after 2 weeks of combination therapy."( Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
Aweeka, FT; Emrick, L; Gambertoglio, JG; Jacobson, MA; Jayewardene, A; Kramer, F; Lizak, P; Polsky, B; Tong, W; van der Horst, C, 1995
)
1.73
"The pharmacodynamic relationship between a range of foscarnet exposure measurements obtained from studying nine patients receiving ongoing maintenance therapy for cytomegalovirus retinitis and a range of efficacy values (days to retinitis progression) obtained by independent examination of serial retinal photographs from the same nine patients was analyzed."( Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis.
Causey, D; Davis, R; Feinberg, J; Heinemann, MH; Jacobson, MA; Kuppermann, BD; Lizak, P; O'Donnell, JJ; Polsky, B; Tong, W, 1994
)
0.76
" In addition, the effects of a combination of foscarnet and ganciclovir were studied, and a pharmacokinetic study to determine the ocular pharmacokinetics of foscarnet after intravitreal injection was carried out."( Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir.
Baudouin, C; Berthe, P; Garraffo, R; Hofmann, P; Lapalus, P; Taburet, AM, 1994
)
0.78
" The apparent elimination rate constant and elimination half-life were not different between dose 1 and steady state."( Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.
Dieterich, DT; Faust, MJ; Johnson, J; Lew, EA; Martin-Munley, S; Nix, D; Poles, MA, 1997
)
0.53
" The mean peak concentration in plasma following the intravenous administration of foscarnet (90 mg/kg) was 887."( Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
Gazzard, BG; Higgs, CJ; Lant, AF; Martin-Munley, S; Noormohamed, FH; Youle, MS, 1998
)
0.77
" Owing to dose-related toxicities associated with these two drugs, it is essential that we have data regarding their pharmacokinetic disposition during concomitant therapy."( Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration?
Aweeka, FT; Botwin, K; Brody, SR; Jacobson, M; Martin-Munley, S,
)
0.39
"To perform a detailed pharmacokinetic study and to evaluate the drug levels reached in the retina after the intravitreal administration of ganciclovir and foscarnet to rabbits."( Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.
Claro-Cala, CM; Cordero, E; López-Cortés, LF; Lucero-Muñoz, MJ; Pastor-Ramos, MT; Ruiz-Valderas, R; Uceda-Montañés, A, 2001
)
0.74
" A noncompartmental pharmacokinetic analysis was used."( Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.
Claro-Cala, CM; Cordero, E; López-Cortés, LF; Lucero-Muñoz, MJ; Pastor-Ramos, MT; Ruiz-Valderas, R; Uceda-Montañés, A, 2001
)
0.54
"The results suggest that the intravitreal administration of ganciclovir has a better pharmacokinetic profile than foscarnet for the treatment of retinitis caused by CMV and other herpes viruses and support the administration of intravitreal ganciclovir twice a week as a treatment for CMV retinitis."( Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.
Claro-Cala, CM; Cordero, E; López-Cortés, LF; Lucero-Muñoz, MJ; Pastor-Ramos, MT; Ruiz-Valderas, R; Uceda-Montañés, A, 2001
)
0.75
" In paediatric patients this may be difficult to achieve due to lack of pharmacokinetic studies, administration of small doses, changes in body composition, continuous growth, and development and maturation of organs and systems."( The pharmacokinetics of antiviral therapy in paediatric patients.
Eksborg, S, 2003
)
0.32
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The aims of the present study were to evaluate foscarnet levels and its pharmacokinetic parameters in vitreous humor and retinal tissue of rabbits after the administration of an intravitreal injection of both liposomal foscarnet and foscarnet commercial solution."( Determination and pharmacokinetic profile of liposomal foscarnet in rabbit ocular tissues after intravitreal administration.
Claro, C; Cordero, E; Jiménez-Castellanos, M; López-Cortés, LF; Lucero, M; Pastor, MT; Ruiz, R, 2009
)
0.86

Compound-Compound Interactions

ExcerptReferenceRelevance
" The combined effect of ddNTPs and the pyrophosphate analog phosphonoformate (PFA) on HIV reverse transcriptase was also examined, and inhibition by PFA in combination with ddTTP or AZTTP was mutually exclusive."( Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
Cheng, YC; Starnes, MC, 1989
)
0.28
" The most potent inhibitor, 3'-fluoro-3'-deoxythymidine, was shown to give synergistic inhibition of HIV-1 replication in combination with the PPi analog phosphonoformate."( Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.
Cox, S; Gilljam, G; Harmenberg, J; Koshida, R; Wahren, B, 1989
)
0.28
" The antiCMV activity of acyclovir in combination with human fibroblast interferon (IFN-beta), phosphonoformic acid (PFA), or trifluorothymidine (TFT) was therefore evaluated."( Effects of acyclovir combined with other antiviral agents on human cytomegalovirus.
Kelley, E; Spector, SA; Tyndall, M, 1982
)
0.26
" They must be administered with caution during pregnancy, because some are known teratogens (e."( Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris, DJ, 1994
)
0.29
" The ability of ISIS 2922 to inhibit replication of HCMV when used in combination with other antiviral agents approved for treatment of HCMV disease was investigated using a 96-well immunoassay."( Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
Anderson, KP; Azad, RF; Brown-Driver, V; Buckheit, RW, 1995
)
0.29
"ACTG 266 was designed as a randomized study to evaluate two doses of the human monoclonal antibody directed against CMV gH (MSL-109) versus placebo, each in combination with standard antiviral therapy for the treatment of newly diagnosed Cytomegalovirus (CMV) retinitis in AIDS patients."( A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re
Alston, B; Asmuth, DM; Aweeka, F; Borucki, MJ; Caliendo, A; Gnann, J; Hirsch, MS; Hubbard, L; Nadler, PI; Nevin, TT; Nokta, M; Owens, S; Pollard, RB; Sattler, F; Spritzler, J; Waterman, K, 2004
)
0.32
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35

Bioavailability

Phosphonoformate (foscarnet; PFA) is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) Its use for the treatment of HIV-1 infection is limited by toxicity and the lack of an orally bioavailable formulation. At low pH, foscarne decomposes via an acid-catalyzed decarboxylation.

ExcerptReferenceRelevance
" The mean oral bioavailability of encapsulated TPFA and PFA was 22 and 8%, respectively."( Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
Bai, SA; de Vera, CC; Loo, TL; Nelson, PD; Straw, JA; Tompkins, WA, 1992
)
0.54
" Mean oral bioavailability was 35% in young cats."( Age-related differences in pharmacokinetics of phosphonoformate in cats.
Mathes, LE; Michael, DF; Polas, PJ; Sams, RA; Swenson, CL, 1990
)
0.28
" In the rabbit the absolute bioavailability after vaginal and topical administration is 14% and 12%, respectively, and in the dog 34% and 3%, respectively."( "Body burden" of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs.
Hussain, AS; Ritschel, WA, 1989
)
0.28
" An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy."( Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Jacobson, MA; Mills, J, 1988
)
0.27
" In vivo drug delivery by liposome encapsulation to overcome problems of bioavailability is currently under study."( Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.
Blay, RA; Buck, SM; Epstein, JS; Geyer, S; Mayner, RE; Pollock, L; Selvam, MP, 1993
)
0.29
" Current work includes the development of increased bioavailability prodrugs (BW 256, famciclovir), which are converted to active drug once absorbed, enabling rapid high serum levels, and hence may turn out to have increased efficacy in HSV- and VZV-induced diseases, for which oral acyclovir currently is the treatment of choice."( Systemic antivirals in herpesvirus infections.
Sacks, SL; Sasadeusz, JJ, 1993
)
0.29
" PFA absorption and bioavailability are increased in animals on phosphate-restricted diets."( Use of phosphonocarboxylic acids as inhibitors of sodium-phosphate cotransport.
Loghman-Adham, M, 1996
)
0.29
" The results suggest that the formulation studied would require significant improvement with respect to tolerability and bioavailability to gain clinical acceptance."( Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
Gazzard, BG; Higgs, CJ; Lant, AF; Martin-Munley, S; Noormohamed, FH; Youle, MS, 1998
)
0.55
" At low pH, foscarnet decomposes via an acid-catalyzed decarboxylation; therefore, poor oral bioavailability might be due to decomposition of foscarnet in gastric acid."( The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet.
Barditch-Crovo, PA; Gambertoglio, J; Hafner, R; Kornhauser, DM; Kuwahara, S; Lietman, PS; Nerhood, LJ; Petty, BG, 1998
)
0.9
" The new methodology may, therefore, be used for fast bioavailability screening of virtual libraries having millions of molecules."( Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Ertl, P; Rohde, B; Selzer, P, 2000
)
0.31
" The use of oral acyclovir preparations with higher bioavailability (valacyclovir) or intravenous acyclovir early on may prevent the considerable morbidity associated with disseminated zoster infection."( Varicella zoster meningoencephalitis following treatment for dermatomal zoster in an alloBMT patient.
Mahendra, P; Osman, H; Tauro, S; Toh, V, 2000
)
0.31
" Valganciclovir, a prodrug of ganciclovir, offers excellent oral bioavailability and is the closest to approval of all the new anti-CMV drugs."( Therapeutic developments in cytomegalovirus retinitis.
Hoffman, VF; Skiest, DJ, 2000
)
0.31
"Phosphonoformate (foscarnet; PFA) is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), but its use for the treatment of HIV-1 infection is limited by toxicity and the lack of an orally bioavailable formulation."( Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.
Aldern, KA; Bazmi, HZ; Beadle, JR; Hammond, JL; Hostetler, KY; Hostetler, SE; Kini, GD; Koontz, DL; Mellors, JW; Richman, DD, 2001
)
0.64
" Afterwards other drugs have been developed either with a better bioavailability or with an activity against aciclovir-resistant strains."( [Antiretroviral drugs for the treatment and prevention of herpes infections in the year 2000].
Malkin, JE, 2002
)
0.31
"Prodrugs of phosphonoformic acid (PFA), an anti-viral agent used clinically as the trisodium salt (foscarnet), are of interest due to the low bioavailability of the parent drug, which severely limits its utility."( Synthesis and stability studies of phosphonoformate-amino acid conjugates: a new class of slowly releasing foscarnet prodrugs.
Kashemirov, BA; Marma, MS; McKenna, CE, 2004
)
0.75
" New antiviral agents are urgently needed with less adverse effects, good oral bioavailability and possibly novel targets or mechanisms of action to avoid cross-resistance and to improve the ability to suppress the selection of resistant virus strains by combination therapy."( Antiviral treatment of cytomegalovirus infection and resistant strains.
Bunjes, D; Härter, G; Mertens, T; Michel, D; Schreiber, A; Schubert, A, 2009
)
0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

Patients were randomized to one of three therapeutic regimens. In these patients a brief course of intravitreal foscarnet, in association with the lowest dosage of the drug administered systematically (90 mg/kg/day), was effective in healing the retinal lesions.

ExcerptRelevanceReference
" The dose-response curves for AMV and RMuLV polymerases primed with (rA)n."( Phosphonoformate inhibits reverse transcriptase.
Oberg, B; Sundquist, B, 1979
)
0.26
" Foscarnet induction therapy was administered at a dosage of 60 mg/kg 3 times/day via 1-hour intravenous infusion for 21 days."( Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Polis, MA, 1992
)
1.46
"Data from human studies were extracted by the author and evaluated according to the patient population studied, sample size, dosage regimen, and therapeutic response."( Treatment of herpesvirus infections in HIV-infected individuals.
Fletcher, CV,
)
0.13
" These data and previous clinical trials demonstrate that this more convenient dosage regimen can be safely used for patients with cytomegalovirus disease."( Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.
Blanshard, C; Dohin, E; Frostegard, C; Gazzard, BG; Gazzard, D; Katlama, C; Singlas, E; Taburet, AM; Zorza, G, 1992
)
0.61
" It is thus difficult to formulate optimal dosing regimens on the basis of what is known of foscarnet pharmacodynamics and pharmacokinetics."( Clinical pharmacology: foscarnet.
Lietman, PS, 1992
)
0.81
" At the high infusion rate, treatment was discontinued after 1-2 days of dosing due to pronounced adverse clinical signs such as extensive vomitings, apathy, ataxia, and muscle spasms."( Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs.
Lundström, J; Nordgren, T; Ryrfeldt, A, 1992
)
0.59
" Nephrotoxicity can be minimized by adjusting dosage according to creatinine clearance and by ensuring that adequate hydration is provided throughout foscarnet therapy."( Review of the toxicities of foscarnet.
Jacobson, MA, 1992
)
0.78
"Foscarnet is a potentially effective and tolerable antiviral agent for patients with acyclovir-resistant, varicella-zoster virus infection; however, the optimal dosage and duration of therapy require further study, as does the relation between clinical findings and in-vitro susceptibility results."( Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection.
Berger, TG; Biron, KK; Gilson, I; Mills, J; Safrin, S; Wofsy, CB; Wolfe, PR, 1991
)
3.17
" In this report, the efficacy, safety, and dosing requirements of foscarnet in a hemodialysis-dependent patient with CMV retinitis are presented."( Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991
)
0.91
" Therefore we began treatment with trisodium phosphonoformate (Foscavir) at a dosage of 60 mg/kg body weight per day (3 weeks), continuing with maintenance therapy at 90 mg/kg body weight per day (7 days a week)."( [Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis].
Gümbel, H; Helm, EB; Ohrloff, C; Schalnus, R, 1991
)
0.28
" The incidence of acute renal failure, which is common during foscarnet therapy, may be reduced by dosage adjustment and adequate prehydration."( Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Chrisp, P; Clissold, SP, 1991
)
1.96
" The serious toxicity associated with zidovudine has led researchers to develop safer dosage regimens."( Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Cersosimo, RJ; Matthews, SJ; Spivack, ML, 1991
)
0.28
" Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir."( Foscarnet sodium.
Baltz, JK; Minor, JR, 1991
)
1.72
"Disodium palmityl phosphonoformate, a novel lipid phosphoester of the anti HIV agent phosphonoformate (foscarnet), inhibits HIV replication in H9 cells and syncytia formation in MOLT-3 cells as effectively as foscarnet itself, as shown by dose-response data from assays for expression of p17 and p24 viral antigens and syncytia formation."( Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins.
Bhongle, NN; Camaioni Neto, C; Piratla, RK; Sarin, PS; Steim, JM; Sun, DK; Turcotte, JG, 1990
)
0.49
"Foscarnet, 60 mg/kg body weight intravenously every 8 hours (with reduced dosage for renal impairment), for 12 to 50 days."( Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989
)
3.16
" Additional studies to determine the optimal dosage for maintenance therapy are needed, as are comparative trials with ganciclovir."( Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Jacobson, MA; Mills, J; O'Donnell, JJ, 1989
)
1.72
" Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days."( Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989
)
0.73
" Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain."( Treatment of CMV retinitis in an AIDS patient.
Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987
)
0.27
" For that reason, most patients have received continued therapy with the drug, most commonly at a dosage of 5-6 mg/(kg."( Treatment of cytomegalovirus retinitis in patients with AIDS.
Cederberg, D; Holland, GN; Jacobson, MA; Mills, J; O'Donnell, JJ,
)
0.13
" These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms."( Antiviral chemotherapy and chemoprophylaxis.
Dolin, R, 1985
)
0.27
" The dosage of Foscarnet was increased during the study."( Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Ahlmén, J; Brynger, H; Lycke, E; Wijnween, AC, 1985
)
0.88
" The animals were treated twice daily in a dosage which gave a minimum serum level of PFA corresponding to an in vitro inhibiting effect on WHV DNA polymerase of about 40%."( No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production.
Hansson, BG; Löfgren, B; Möller-Nielsen, C; Nordenfelt, E; Oberg, B; Widell, A, 1982
)
0.26
" In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg."( Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines.
Hsiung, GD; Mayo, DR, 1984
)
0.27
" Reversible nephrotoxicity is common during foscarnet therapy, but may be reduced by dosage adjustment and adequate hydration."( Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Bryson, HM; Wagstaff, AJ, 1994
)
1.99
"These plasma data suggest that further dosage adjustments are unnecessary for or alternating maintenance therapy."( Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
Aweeka, FT; Emrick, L; Gambertoglio, JG; Jacobson, MA; Jayewardene, A; Kramer, F; Lizak, P; Polsky, B; Tong, W; van der Horst, C, 1995
)
1.73
" The dosing regimen for induction combination therapy was ganciclovir at 5 mg/kg every 12 hours and foscarnet at 60 mg/kg every 8 hours."( Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Flores-Aguilar, M; Freeman, WR; Kuppermann, BD; Quiceno, JI; Rickman, LS, 1993
)
0.8
" Further work to delineate the optimal dosing and indications for combination therapy will be important."( Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Flores-Aguilar, M; Freeman, WR; Kuppermann, BD; Quiceno, JI; Rickman, LS, 1993
)
0.58
" Furthermore, there was no increase in the creatinine or blood urea nitrogen level after 2 weeks of treatment with LE-PFA at a dosage of 35 mg/kg/day."( Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.
Beauchamp, D; Bergeron, MG; Désormeaux, A; Dusserre, N; Omar, RF; Poulin, L; Tremblay, M, 1995
)
0.59
"Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)."( Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration
, 1996
)
0.9
" In these patients a brief course of intravitreal foscarnet, in association with the lowest dosage of the drug administered systematically (90 mg/kg/day), was effective in healing the retinal lesions."( Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis.
Baldanti, F; Cadrobbi, P; Gerna, G; Masiero, G; Scaggiante, R; Secchi, AG; Tognon, MS; Turrini, B,
)
0.68
" However, patients with positive baseline CMV blood cultures had a significantly more shallow dose-response curve."( Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients.
Aweeka, F; Drusano, GL; Eaton, C; Gambertoglio, J; Jacobson, M; Lane, HC; Martin-Munley, S; Polis, M, 1996
)
0.61
" Two patients developed mild serum-creatinine increases requiring adjustment of the foscarnet dosage according to protocol."( Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients.
Aschan, J; Ehrnst, A; Ljungman, P; Lönnqvist, B; Oberg, G; Pauksen, K; Sulila, P, 1996
)
1.96
"Since incremental increases in residual clearance of 30% or more generally will result in clinically significant changes in a drug's serum concentration, foscarnet dosage needs to be individualized for patients receiving peritoneal dialysis."( Disposition of foscarnet during peritoneal dialysis.
Akers, A; Alexander, AC; Aweeka, FT; Fraley, DS; Matzke, GR, 1996
)
0.84
" New modes of treatment have attempted to prolong intervals between dosing and reduce drug-related toxicity in an effort to improve quality of life."( Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities.
Bright, DC, 1997
)
0.3
" Other new methods involve liposomal systems to increase drug contact time, use of longer-acting drugs with less-frequent dosing requirements, and methods to improve quality of life by avoiding intravenous drug delivery."( Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities.
Bright, DC, 1997
)
0.3
" The dosing regimen for induction with the combined therapy was foscarnet (60 mg/kg every 8 hours) and ganciclovir (5 mg/kg daily for 3 weeks)."( Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis.
Lewis, LL; Mueller, BU; Nussenblatt, RB; Pizzo, PA; Walton, RC; Whitcup, SM, 1995
)
0.8
" Twelve patients randomly received either foscarnet (four doses) or zalcitabine (five doses) (Phase 1), followed by concomitant foscarnet (four doses) and zalcitabine (six doses) (Phase 2), followed by dosing with the drug not received in Phase 1 (Phase 3)."( Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration?
Aweeka, FT; Botwin, K; Brody, SR; Jacobson, M; Martin-Munley, S,
)
0.65
" New dosage forms were well tolerated by the animals, causing no manifest symptoms of intoxication irrespective of the doses or protocols of the drug use, Foscarnet in any dosage form in the total daily dose of at least 120 mg/kg had a pronounced antiviral effect towards herpes simplex type II virus, comparable with that of the commercial reference drug virolex: the intensity of clinical symptoms was alleviated and the disease duration shortened."( [Evaluation of antiviral activity of new medicinal forms of foscarnet in genital herpes in guinea pigs].
Alimbarova, LM; Barinskiĭ, IF; Kuz'min, KK,
)
0.57
" To develop specific dosage guidelines, information on the disposition of this compound in patients with varying degrees of renal function and those requiring dialysis is essential."( Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations.
Aweeka, FT; Gambertoglio, JG; Hedman, A; Jacobson, MA; Martin-Munley, S; Omachi, R; Schoenfeld, P; Tsunoda, S, 1999
)
0.56
"These data indicate that substantial dosage adjustments must be made in renal failure patients."( Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations.
Aweeka, FT; Gambertoglio, JG; Hedman, A; Jacobson, MA; Martin-Munley, S; Omachi, R; Schoenfeld, P; Tsunoda, S, 1999
)
0.56
"The P & T Committee at Trinity Lutheran Hospital, a 320-bed, community/teaching hospital in Kansas City, MO, has developed dosing and monitoring guidelines for foscarnet sodium (Foscavir) and trimetrexate glucuronate (Neutrexin)--two drugs used to treat patients with opportunistic infections associated with the human immunodeficiency virus (HIV)."( Dosing guidelines for foscarnet and trimetrexate.
Chase, K; Henry, RB; O'Connor, MC; Wooten, JM, 1995
)
0.8
" Continued induction dosing or re-induction may protect against early breakthrough CMV disease and CMV-related death among patients with rising antigenemia on preemptive therapy."( Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
Boeckh, M; Corey, L; Davis, C; Drew, WL; Gooley, T; Huang, M; Miner, R; Nichols, WG, 2001
)
0.31
" The emergence of drug resistance may be reduced by optimization of host immunity, use of potent antiviral drug regimens, and adherence to dosing regimens that adequately suppress viral replication."( Cytomegalovirus drug resistance and clinical implications.
Chou, SW, 2001
)
0.31
" In patients with renal insufficiency, careful dosage adjustment is mandatory to optimize drug exposure and reduce the risk for adverse events."( Anti-viral drugs in continuous ambulatory peritoneal dialysis (CAPD).
Deray, G; Issad, B; Izzedine, H; Launay-Vacher, V, 2002
)
0.31
" The dosage of foscarnet should be 40 milligrams per kilogram three times per day or 60 milligrams per kilogram twice daily."( Management of acyclovir-resistant herpes simplex virus.
Chilukuri, S; Rosen, T, 2003
)
0.67
" The selected compounds differed by the slopes of their dose-response curve: compounds with a slope of 1 (GCV) representing one target or noncooperativity and compounds with high slopes indicating positive cooperativity."( In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.
Arav-Boger, R; Cai, H; Forman, M; He, R; Kapoor, A; Posner, GH; Venkatadri, R, 2014
)
0.4
"Suboptimal dosing of valGCV is associated with development of GCV-R CMV."( Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Angarone, M; Flaherty, J; Ison, MG; Penugonda, S; Rubin, J; Stosor, V; Young, PG, 2016
)
0.43
" Optimal dosing strategies in recipients with impaired kidney function remain undefined, with limited pharmacokinetic data to date."( Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017
)
0.46
" Insufficient dosing regimens or prolonged treatment with TK inhibitors result in the local selection of pre-existing mutant HSV viruses."( [Acyclovir-resistant perineal HSV infection revealing chronic lymphoid leukaemia].
Bulai Livideanu, C; Casassa, EA; Fortenfant, F; Gaudin, C; Konstantinou, MP; Lamant, L; Mengelle, C; Nicol, P; Paul, C; Viraben, R, 2018
)
0.48
" While on maintenance dosing of oral valacyclovir, he experienced reactivation in the form of bilateral vasculitis, which was successfully managed once restarting therapeutic oral dosing."( Case Report: Varicella-zoster Encephalitis with Acute Retinal Necrosis and Oculomotor Nerve Palsy.
Quan, SC; Skondra, D, 2019
)
0.51
" Chronic suppression with oral antiviral therapy after ARN is recommended to prevent involvement of the contralateral eye, though there is no consensus on the duration and dosage of antivirals."( Acute retinal necrosis in a patient with remote severe herpes simplex encephalitis.
Kobayashi, T; Meier, J; Sekar, P; Streit, J, 2019
)
0.51
" Foscarnet dosing used in practice may be discordant with what is recommended in product labeling, as the result of an unconventional dosing nomogram or prescriber preference; however, it is unknown how discordant foscarnet dosing affects outcomes."( Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019
)
1.8
"Our purpose was to characterize the relationship between initial foscarnet dosing intensity (relative to product labeling) and key effectiveness and safety endpoints."( Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019
)
1.13
" There was no association between initial foscarnet dosing intensity and acute kidney injury, hematologic toxicity, or mortality (24% in both groups)."( Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019
)
1.16
"These findings suggest outcomes may be sensitive to other factors and underscore the need for further studies to improve understanding of foscarnet dosing in immunosuppressed patients."( Recommended foscarnet dose is not associated with improved outcomes in cytomegalovirus salvage therapy.
Athans, V; Koval, CE; Lam, SW; Spinner, ML, 2019
)
1.1
" In the earliest published small case series investigating the optimal infusion modality, patients with acquired immunodeficiency syndrome (AIDS) due to the human immunodeficiency virus (HIV) received either continuous infusion or intermittent dosing of foscarnet."( Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients.
Brown, JW; Domingo, W; Johnsrud, JJ; Nguyen, IT, 2021
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
sodium-dependent Pi-transporter inhibitorAny substance that inhibits the action of sodium-dependent Pi-transporters.
HIV-1 reverse transcriptase inhibitorAn entity which inhibits the activity of HIV-1 reverse transcriptase.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
phosphonic acidsHP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives.
carboxylic acidA carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid.
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 2Homo sapiens (human)Ki14,200.00000.00000.72369.9200AID238755
DNA polymerase catalytic subunitHuman herpesvirus 5 strain AD169IC50 (µMol)2.50000.40001.31742.5000AID255119; AID307427
DNA polymerase catalytic subunitHuman herpesvirus 3 strain DumasIC50 (µMol)0.28000.28001.93005.8000AID255144
DNA polymerase alpha catalytic subunitHomo sapiens (human)IC50 (µMol)20.00001.00002.74294.3000AID255106
Carbonic anhydrase 4Homo sapiens (human)Ki820.00000.00021.97209.9200AID238915
DNA polymerase delta catalytic subunitHomo sapiens (human)IC50 (µMol)20.00002.30002.30002.3000AID255107
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki41,700.00000.00001.27259.9000AID239032
Carbonic anhydrase 9Homo sapiens (human)Ki2,210.00000.00010.78749.9000AID239054
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)11.34440.00011.076810.0000AID1188667; AID1188672; AID1188674; AID1188676; AID1389753; AID199100; AID199101; AID360704; AID360705
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, probable fosfomycin resistance proteinPseudomonas aeruginosa PAO1Kd0.20000.20000.20000.2000AID977611
Chain B, probable fosfomycin resistance proteinPseudomonas aeruginosa PAO1Kd0.20000.20000.20000.2000AID977611
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd7.15000.00062.40599.8000AID360404; AID360405
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)KA12.00000.02001.72197.4000AID238032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
DNA repairDNA polymerase alpha catalytic subunitHomo sapiens (human)
nucleotide-excision repairDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA synthesis involved in UV-damage excision repairDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA synthesis involved in DNA repairDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA replicationDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA replication, synthesis of primerDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA replication initiationDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA strand elongation involved in DNA replicationDNA polymerase alpha catalytic subunitHomo sapiens (human)
leading strand elongationDNA polymerase alpha catalytic subunitHomo sapiens (human)
lagging strand elongationDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA repairDNA polymerase alpha catalytic subunitHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA polymerase alpha catalytic subunitHomo sapiens (human)
regulation of type I interferon productionDNA polymerase alpha catalytic subunitHomo sapiens (human)
mitotic DNA replication initiationDNA polymerase alpha catalytic subunitHomo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
DNA synthesis involved in DNA repairDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA replicationDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA-templated DNA replicationDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA repairDNA polymerase delta catalytic subunitHomo sapiens (human)
base-excision repair, gap-fillingDNA polymerase delta catalytic subunitHomo sapiens (human)
nucleotide-excision repair, DNA gap fillingDNA polymerase delta catalytic subunitHomo sapiens (human)
response to UVDNA polymerase delta catalytic subunitHomo sapiens (human)
cellular response to UVDNA polymerase delta catalytic subunitHomo sapiens (human)
fatty acid homeostasisDNA polymerase delta catalytic subunitHomo sapiens (human)
error-free translesion synthesisDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA biosynthetic processDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA replication proofreadingDNA polymerase delta catalytic subunitHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
nucleotide bindingDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA bindingDNA polymerase alpha catalytic subunitHomo sapiens (human)
chromatin bindingDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA-directed DNA polymerase activityDNA polymerase alpha catalytic subunitHomo sapiens (human)
protein bindingDNA polymerase alpha catalytic subunitHomo sapiens (human)
zinc ion bindingDNA polymerase alpha catalytic subunitHomo sapiens (human)
protein kinase bindingDNA polymerase alpha catalytic subunitHomo sapiens (human)
DNA replication origin bindingDNA polymerase alpha catalytic subunitHomo sapiens (human)
single-stranded DNA bindingDNA polymerase alpha catalytic subunitHomo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
nucleotide bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
chromatin bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
damaged DNA bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
DNA-directed DNA polymerase activityDNA polymerase delta catalytic subunitHomo sapiens (human)
protein bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
enzyme bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
metal ion bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
4 iron, 4 sulfur cluster bindingDNA polymerase delta catalytic subunitHomo sapiens (human)
3'-5'-DNA exonuclease activityDNA polymerase delta catalytic subunitHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nucleusDNA polymerase alpha catalytic subunitHomo sapiens (human)
nuclear envelopeDNA polymerase alpha catalytic subunitHomo sapiens (human)
nucleoplasmDNA polymerase alpha catalytic subunitHomo sapiens (human)
alpha DNA polymerase:primase complexDNA polymerase alpha catalytic subunitHomo sapiens (human)
nucleolusDNA polymerase alpha catalytic subunitHomo sapiens (human)
cytosolDNA polymerase alpha catalytic subunitHomo sapiens (human)
nuclear matrixDNA polymerase alpha catalytic subunitHomo sapiens (human)
chromatinDNA polymerase alpha catalytic subunitHomo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
chromosome, telomeric regionDNA polymerase delta catalytic subunitHomo sapiens (human)
nucleusDNA polymerase delta catalytic subunitHomo sapiens (human)
nucleoplasmDNA polymerase delta catalytic subunitHomo sapiens (human)
cytosolDNA polymerase delta catalytic subunitHomo sapiens (human)
membraneDNA polymerase delta catalytic subunitHomo sapiens (human)
aggresomeDNA polymerase delta catalytic subunitHomo sapiens (human)
delta DNA polymerase complexDNA polymerase delta catalytic subunitHomo sapiens (human)
nucleotide-excision repair complexDNA polymerase delta catalytic subunitHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (301)

Assay IDTitleYearJournalArticle
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID365176Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID85399Antiviral activity against DNA polymerase mutant resistant to PFA 3b(PFA) was determined at a conc of 50 uM1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID82065Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Design, synthesis, and antiviral evaluation of 2-substituted 4,5-dichloro- and 4,6-dichloro-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
AID360398Inhibition of HIV1 reverse transcriptase p66/p51 mediated DNA synthesis using polypurine tract primer assessed as DNA bands at position +3 by polyacrylamide gel electrophoresis2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID278226Antiviral activity against Human CMV T2296 in MRC5 cells by PRA2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID82066Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
AID82525Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Syntheses and structure--activity relationships of novel apio and thioapio dideoxydidehydronucleosides as anti-HCMV agents.
AID80124Antiviral activity was determined against Human cytomegalovirus (HCMV) strain AD-169 using CPE inhibition assay2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Syntheses and structure--activity relationships of novel apio and thioapio dideoxydidehydronucleosides as anti-HCMV agents.
AID1188673Inhibition of wild type HIV1 reverse transcriptase K65R mutant assessed as inhibition of DNA primer extension using [8-3H(N)]-dATP by scintillation proximity assay relative to wild type2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID307428Inhibition of HSV1 DNA polymerase by scintillation proximity assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases.
AID80099Antiviral activity assayed by ability to inhibit Towne strain of HCMV virus1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Design, synthesis, and antiviral activity of alpha-nucleosides: D- and L-isomers of lyxofuranosyl- and (5-deoxylyxofuranosyl)benzimidazoles.
AID392515Antiviral activity against Human cytomegalovirus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID278222Antiviral activity against Human CMV T2293 in HFF cells by PRA2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID340470Inhibition of human polymerase gamma by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition.
AID372975Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2420 pol G841A mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID393964Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID393989Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID575025Antiviral activity against Herpes simplex virus 1 isolate 10 harboring N23S, K36E, R89Q, A265T C336Y mutations in thymidine kinase and S33G, A330R, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID574825Antiviral activity against Herpes simplex virus 1 isolate 5 harboring N23S, K36E, A192V, G251C, A265T, V267L, P268T, -1G 856 = frameshift mutations in thymidine kinase and A330R, V905M, T1208A, H98Y mutations in DNA polymerase infected in african green mo2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID85395Antiviral activity against DNA polymerase mutant resistant to KOS(parental) was determined at a conc of 50 uM1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID340465Inhibition of HSV1 DNA polymerase by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition.
AID278217Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID412415Antiviral activity against acyclovir-resistant HSV1 KOS-M isolate replication in african green monkey Vero cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID1389754Inhibition of HIV1 reverse transcriptase p66/p51 assessed as freezing of template-primer-enzyme complex at pretranslocated stage at 100 uM using 5'-radiolabeled PBS36c DNA/5'-TTCTGACTAAAAGGGTCTGAGGGAT-3 as template/primer preincubated for 10 mins followed2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively "Freeze" the pre-translocated complex during the polymerization catalytic cycle.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID181835In vitro inhibition of Na(+)-gradient-dependent uptake of 32 inorganic phosphate (Pi) by BBM vesicles freshly prepared from the rat renal cortex1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Alpha-halo [(phenylphosphinyl)methyl]phosphonates as specific inhibitors of Na(+)-gradient-dependent Na(+)-phosphate cotransport across renal brush border membrane.
AID238755Binding affinity towards human cytosolic carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates.
AID291764Inhibition of HIV1 reverse transcriptase at 20 ug/mL2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and biological evaluation of N-acetyl-beta-aryl-1,2-didehydroethylamines as new HIV-1 RT inhibitors in vitro.
AID575033Antiviral activity against Herpes simplex virus 2 isolate 18 harboring A27T, G39E, N78D, -1C 556 = Stop 263, S29A mutations in thymidine kinase and A9T, P15S, L60P, E678G, del, DD676-677 mutations in DNA polymerase infected in african green monkey Vero ce2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID412422Antiviral activity against ganciclovir-resistant HCMV U405 isolate replication in HFF cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID79955Concentration required for 50% inhibition of HCMV replication was measured using a Plaque reduction assay1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Design, synthesis, and antiviral evaluation of 2-substituted 4,5-dichloro- and 4,6-dichloro-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID90788Activity against human cytomegalovirus (HCMV) using plaque reduction assay1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles.
AID340466Inhibition of VZV DNA polymerase by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition.
AID372965Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID326138Cytotoxicity against african green monkey Vero cells after 2 days2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID199100Inhibitory concentration against wild type HIV-1 reverse transcriptase (RT) using poly rC.dG as the template or primer2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID82258Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Synthesis and antiviral evaluation of trisubstituted indole N-nucleosides as analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole (TCRB).
AID1354897Inhibition of human NaPi2a expressed in HEK293 cells coexpressing tetracyclin assessed as reduction in uptake of 33P-radiolabeled Pi at 5 mM incubated for 20 to 30 mins prior to substrate addition2018ACS medicinal chemistry letters, May-10, Volume: 9, Issue:5
Discovery of Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1).
AID575039Antiviral activity against Herpes simplex virus 2 isolate 24 harboring G39E, -1G 440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E139K, H837R mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID299440Inhibition of HSV1 DNA polymerase2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase.
AID250867Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 400 mg/kg; expressed as number of survivors/102005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID326136Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID32219Minimum inhibitory concentration of the compound, achieving a complete protection of ATH8 cells against the cytopathic effect of HTLV-III / LAV reverse transcriptase1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID156203Binding to POPC/GMI liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID85397Antiviral activity against DNA polymerase mutant resistant to PFA 1a (PFA) was determined at a conc of 50 uM1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID15120Percent of the drug absorbed after administration to humans was determined1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID278220Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID393987Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID250797Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 200 mg/kg; expressed as mean day of death2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID87969Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (Brand) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID80125Antiviral activity was determined against Human cytomegalovirus (HCMV) strain Davis using CPE inhibition assay2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Syntheses and structure--activity relationships of novel apio and thioapio dideoxydidehydronucleosides as anti-HCMV agents.
AID360394Inhibition of HIV1 reverse transcriptase p66/p51 mediated single strand incorporation into DNA at +4 position using polypurine tract PPT+4/PPT57 template after 7 mins by gel based assay2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID71777Concentration that reduces Friend murine leukemia virus titer by 50%1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID278227Antiviral activity against Human CMV T2287 in MRC5 cells by PRA2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1188667Inhibition of wild type HIV1 reverse transcriptase assessed as inhibition of DNA primer extension using [8-3H(N)]-dATP by scintillation proximity assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase.
AID1188676Inhibition of wild type HIV1 reverse transcriptase M184V mutant assessed as inhibition of DNA primer extension using [8-3H(N)]-dATP by scintillation proximity assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1389503Inhibition of DHBV DNA polymerase derived from infected duckling liver assessed as decrease in biotin-11-dUTP incorporation using poly (A)/oligo(dT)15 as template/primer after 1 hr by ELISA2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors.
AID236916Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID570166Antiviral activity against DHBV infected in human HepG2(2.2.15) cells assessed as reduction of viral DNA level after 9 days by RT-PCR analysis2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID232925selectivity index expressed as TC50/EC50; EC50 values are calculated from CEM lymphoblast cells infected with HIV-1LAI virus.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID239054Binding affinity owards recombinant human transmembrane carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates.
AID142440Cytotoxicity was evaluated and represented as IC50.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID372967Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID250793Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as mean day of death2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID87847Minimum inhibitory concentration causing 25% inhibition cytopathic effect induced by Herpes simplex virus-1 (Brand) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID393991Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID105162Effective concentration required to inhibit HIV-2 induced cytopathicity in human MT-4 cell lines2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID575029Antiviral activity against Herpes simplex virus 2 isolate 14 harboring G39E, N78D, M70R mutations in thymidine kinase and A724V mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID104781Cytostatic concentration required to reduce MT-4 cell viability in mock-infected cell cultures2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID255119Inhibition of human cytomegalovirus DNA polymerase (95 uL) activity in a solution containing 6.4 mM HEPES (pH 7.5), incubation for 12 minutes at 26 degrees C2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
AID681778TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Foscarnet: 1000 uM) in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
AID574823Antiviral activity against Herpes simplex virus 1 isolate 3 harboring N23S, K36E, R89Q, A265T, Y53D mutations in thymidine kinase and S33G, A330R, V905M, E1005K mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID326134Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID412421Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID278223Antiviral activity against Human CMV T2291 in HFF cells by PRA2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID575040Antiviral activity against Herpes simplex virus 2 isolate 25 harboring I101S mutations in thymidine kinase and D785N, V544A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID250795Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 400 mg/kg; expressed as mean day of death2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID1188677Inhibition of wild type HIV1 reverse transcriptase M184V mutant assessed as inhibition of DNA primer extension using [8-3H(N)]-dATP by scintillation proximity assay relative to wild type2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase.
AID372968Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID291760Inhibition of HIV1 reverse transcriptase2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and biological evaluation of N-acetyl-beta-aryl-1,2-didehydroethylamines as new HIV-1 RT inhibitors in vitro.
AID412420Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID681387TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Sep, Volume: 294, Issue:3
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
AID42620Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID82537Cytostatic concentration required to inhibit HEL cell proliferation measured at day 42004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism.
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID156089Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID42622Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
AID82260Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration.1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Design, synthesis, and antiviral activity of alpha-nucleosides: D- and L-isomers of lyxofuranosyl- and (5-deoxylyxofuranosyl)benzimidazoles.
AID87998Minimum inhibitory concentration causing 25% inhibition cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in HEp -2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID360405Binding affinity to HIV1 reverse transcriptase p66/p51-polypurine tract primer complex in absence of Mg2+ ions by band shift assay2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID574829Antiviral activity against Herpes simplex virus 1 isolate 9 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and S33G, A330R, V905M, A1203T, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by 2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID199101Inhibitory concentration against wild type HIV-1/138Lys reverse transcriptase (RT) using [3H]dGTP as a radioligand2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID307427Inhibition of HCMV DNA polymerase by scintillation proximity assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID393993Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID278225Antiviral activity against Human CMV Towne in MRC5 cells by PRA2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID18847Percent of drug absorbed by human intestine after oral administration2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
AID167150Minimum cytotoxic concentration causing toxic effects on uninfected cells in rabbit1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID239032Binding affinity towards recombinant human mitochondrial carbonic anhydrase V2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID575037Antiviral activity against Herpes simplex virus 2 isolate 22 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E678G, Y823C mutations in DNA polymerase infected in african green monkey Vero cells by pla2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID679724TP_TRANSPORTER: uptake of Foscarnet at a concentration of 3uM in MCT1-expressing MDA-MB231 cells1999The Journal of pharmacy and pharmacology, Oct, Volume: 51, Issue:10
Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1.
AID278219Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID235800Selectivity index which is the ratio of IC50 to EC50 of R-MuLV.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID238915Binding affinity towards human membrane associated carbonic anhydrase IV2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates.
AID570167Cytotoxicity against human HepG2(2.2.15) cells after 9 days2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70.
AID563744Antiviral activity against HSV2 MS infected in HFF after 3 days by plaque reduction assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
AID334987Inhibition of HIV reverse transcriptase assessed as incorporation of [3H]dTMP at 0.6 uM
AID42621Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
AID46179Effective concentration required to inhibit HIV-1 induced cytopathicity in human CEM cell lines2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID360705Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA PPT primed substrate by scintillation proximity assay2007The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11
HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID372977Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2417 pol A809V mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID82426Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Synthesis and antiviral evaluation of trisubstituted indole N-nucleosides as analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole (TCRB).
AID87970Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID575032Antiviral activity against Herpes simplex virus 2 isolate 17 harboring G39E, N78D Q222Stop mutations in thymidine kinase and A9T, P15S, L60P, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID85559Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 1.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID255107Inhibition of human delta DNA polymerase (95 uL) activity in a solution containg 6.4 mM HEPES (pH 7.5) upon incubation for 12 minutes at 26 degrees C with the compound dissolved in DMSO2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
AID278215Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID575034Antiviral activity against Herpes simplex virus 2 isolate 19 harboring G39E, +2G 439-440 = Stop 184 mutations in thymidine kinase and A9T, P15S, L60P, del, DGDE683-686 mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduc2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID575028Antiviral activity against Herpes simplex virus 2 isolate 13 harboring, M183I mutations in thymidine kinase and A9T, P15S, R41H, L60P, E139K, A232T mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID299437Inhibition of human cytomegalovirus DNA polymerase2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID393992Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID575031Antiviral activity against Herpes simplex virus 2 isolate 16 harboring D137Stop mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID481581Inhibition of HCMV DNA polymerase infected in HFF cells2010Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10
Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility.
AID278224Antiviral activity against Human CMV T2311 in HFF cells by PRA2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID365170Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID574824Antiviral activity against Herpes simplex virus 1 isolate 4 harboring N23S, K36E -1C 553 = frameshift mutations in thymidine kinase and S33G, A330R, A899V, L1188F mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction 2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID82693Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism.
AID278221Antiviral activity against Human CMV AD169 in HFF cells by PRA2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID85552Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
7-Aminoquinolines. A novel class of agents active against herpesviruses.
AID575035Antiviral activity against Herpes simplex virus 2 isolate 20 harboring G39E, -1C 467 = Stop 183 mutations in thymidine kinase and A9T, P15S, L60P, E139K, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID1188674Inhibition of wild type HIV1 reverse transcriptase E89T mutant assessed as inhibition of DNA primer extension using [8-3H(N)]-dATP by scintillation proximity assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID570168Selectivity index, ratio of IC50 for HBV to TD50 for human HepG2(2.2.15) cells2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70.
AID372974Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2417 pol A809V mutant to EC50 for Cytomegalovirus CMV T2211 by plaque reduction assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID365164Inhibition of HCMV UL54-encoded DNA polymerase at 5 to 7.5 uM after 60 mins2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID574826Antiviral activity against Herpes simplex virus 1 isolate 6 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 225 mutations in thymidine kinase and S33G, A330R, A646T, S1123L, P1124H, T1208A, R1229I mutations in DNA polymerase infected in african green monke2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID340464Inhibition of HCMV DNA polymerase by scintillation proximity assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition.
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID235581In vitro therapeutic index as ratio of cytotoxicity to inhibition of viral replication1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
7-Aminoquinolines. A novel class of agents active against herpesviruses.
AID229707Fold-R is the ratio of EC50 of mutant HIV-1W88G to the average EC50 of HIV-1(LAI)2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID82692Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism.
AID250870Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 400 mg/kg; expressed as number of survivors/102005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID574828Antiviral activity against Herpes simplex virus 1 isolate 8 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and A330R, P875S, V905M, P1124H, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID1188672Inhibition of wild type HIV1 reverse transcriptase K65R mutant assessed as inhibition of DNA primer extension using [8-3H(N)]-dATP by scintillation proximity assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase.
AID250987Effect on ocular HSV-2 reactivation in mice following intraperitoneal dosage at 200 mg/kg; expressed as HSV-2 positive cultures/15 mice2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID360399Inhibition of HIV1 reverse transcriptase p66/p51 mediated DNA synthesis using polypurine tract primer assessed as DNA bands at position +16 by polyacrylamide gel electrophoresis2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID89163Anti-HIV activity against PFA-resistant mutant HIV-1(LAI) strain in P4/R5 cells2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID575030Antiviral activity against Herpes simplex virus 2 isolate 15 harboring R221H mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID278216Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID250865Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as number of survivors/102005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID574821Antiviral activity against Herpes simplex virus 1 isolate 1 harboring C6G N23S K36E L42P G240E A265T and A207P mutations in thymidine kinase and S33G, A330R, N425T, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque re2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID250868Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as number of survivors/102005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID87978Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-1 in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID360396Inhibition of HIV1 reverse transcriptase p66/p51 mediated single strand incorporation into DNA at +16 position using polypurine tract PPT+16/PPT57 template after 7 mins by gel based assay2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID278218Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID299448Inhibition of human DNA polymerase gamma2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase.
AID84636compound was tested for 50% toxic concentration by visual grading scale of cells after 3 days of drug treatment in HT4-6C cells.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID365172Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID360403Inhibition of HIV1 reverse transcriptase p66/p51 at pre-translocated state using polypurine tract primer+16 substrate by potassium peroxynitrite based site-specific foot printing method2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID87974Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID89164Anti-HIV activity against PFA-resistant mutant HIV-1W88G strain in P4/R5 cells2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID255144Inhibition of Varicella-Zoster virus DNA polymerase (95 uL) activity in a solution containing 6.4 mM HEPES (pH 7.5), incubation for 12 minutes at 26 degrees C; [nd = not determined]2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
AID105161Effective concentration required to inhibit HIV-1E138K induced cytopathicity in human MT-4 cell lines2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID365169Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID575027Antiviral activity against Herpes simplex virus 2 isolate 12 harboring G39E, N78D, L140F, S66P, A72S mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1188675Inhibition of wild type HIV1 reverse transcriptase E89T mutant assessed as inhibition of DNA primer extension using [8-3H(N)]-dATP by scintillation proximity assay relative to wild type2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase.
AID574827Antiviral activity against Herpes simplex virus 1 isolate 7 harboring N23S, K36E, R89Q, +1C 464-465 = Stop 228 mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, A870G mutations in DNA polymerase infected in african green monkey Vero cells by 2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID211663compound was tested for 50% toxic concentration by visual grading scale of cells after 3 days of drug treatment in CEM lymphoblast cells.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
AID19212Partition coefficient (logP)2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID236913Permeability Coefficient in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID412414Antiviral activity against acyclovir-sensitive HSV1 KOS isolate replication in african green monkey Vero cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID167149Minimum cytotoxic concentration of compound causing toxic effects on uninfected cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID575026Antiviral activity against Herpes simplex virus 1 isolate 11 harboring N23S, K36E, G251C, A265T, P268T, R176W mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, S724N, V117L, L267M mutations in DNA polymerase infected in african green monkey V2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID255106Inhibition of human alpha DNA polymerase (95 uL) activity in a solution containg 6.4 mM HEPES (pH 7.5) upon incubation for 12 minutes at 26 degrees C with the compound dissolved in DMSO2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID250869Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 200 mg/kg; expressed as number of survivors/102005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID326135Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID250794Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 200 mg/kg; expressed as mean day of death2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID355900Inhibition of HIV1 reverse transcriptase assessed as residual enzyme activity at 10 uM2003Journal of natural products, May, Volume: 66, Issue:5
Two new xanthone derivatives from the algicolous marine fungus Wardomyces anomalus.
AID412418Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID85401Antiviral activity against DNA polymerase mutant resistant to PFA 5a(PFA) was determined at a conc of 50 uM1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Acetylenic nucleosides. 4. 1-beta-D-arabinofuranosyl-5-ethynylcytosine. Improved synthesis and evaluation of biochemical and antiviral properties.
AID80103Concentration required for 50% inhibition of HCMV replication was measured using a Plaque reduction assay1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Design, synthesis, and antiviral evaluation of 2-chloro-5,6-dihalo-1-beta-D-ribofuranosylbenzimidazoles as potential agents for human cytomegalovirus infections.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID307429Inhibition of VZV DNA polymerase by scintillation proximity assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases.
AID238032Activation constant towards human cytosolic carbonic anhydrase I; Activator2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID464096Inhibition of HCMV recombinant DNA polymerase expressed in baculovirus infected SF9 cells after 12 mins by scintillation proximity assay2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase.
AID299441Inhibition of VZV DNA polymerase2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID575036Antiviral activity against Herpes simplex virus 2 isolate 21 harboring G39E, N78D, L140F, -1C 452 = Stop 183 mutations in thymidine kinase and P15S, L60P, E678G mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID372966Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID105160Effective concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 cell lines2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID412417Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID365174Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID360404Binding affinity to HIV1 reverse transcriptase p66/p51-polypurine tract primer complex in presence of Mg2+ ions by band shift assay2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID393988Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID1389753Inhibition of HIV1 reverse transcriptase p66/p51 polymerase using PPT57 DNA/Cy5-labeled PPT24 as template/primer preincubated for 10 mins followed by dNTP addition measured after 5 mins by bromophenol blue staining based phosphor imaging analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively "Freeze" the pre-translocated complex during the polymerization catalytic cycle.
AID250796Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 100 mg/kg; expressed as mean day of death2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID87977Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-1 (thymidine kinase deficient) in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID18849Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID365171Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID372976Drug resistance, ratio of EC50 for Cytomegalovirus CMV T5242 pol T813S mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID232926selectivity index expressed as TC50/EC50; EC50 values are calculated from HT4-C6 cells infected with HIV-1LAI1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
AID372962Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID372961Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID372964Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID574822Antiviral activity against Herpes simplex virus 1 isolate 2 harboring C6G, N23S, K36E, R41H, A192V, A265T, L170P mutations in thymidine kinase and S33G, A330R, N425T, V905M, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID372963Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID563782Antiviral activity against 4'-thioIDU-resistant HSV2 infected in HFF after 3 days by plaque reduction assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
AID87971Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by herpes simplex virus (HSV)-1 (K979) in vero cells.1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID563783Selectivity ratio of EC50 for 4'-thioIDU-resistant HSV2 infected in HFF to EC50 for HSV2 MS infected in HFF2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
AID87972Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID88116Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID412416Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID82062Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles.
AID563784Antiviral activity against HSV2 harboring frameshift mutation in TK infected in HFF after 3 days by plaque reduction assay2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.
AID46180Effective concentration required to inhibit HIV-2 induced cytopathicity in human CEM cell lines2004Journal of medicinal chemistry, Jun-17, Volume: 47, Issue:13
Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID85548In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
7-Aminoquinolines. A novel class of agents active against herpesviruses.
AID360397Inhibition of HIV1 reverse transcriptase E89K mutant mediated single strand incorporation into DNA at +16 position using polypurine tract PPT+16/PPT57 template after 7 mins by gel based assay2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID575038Antiviral activity against Herpes simplex virus 2 isolate 23 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, I291V mutations in DNA polymerase infected in african green monkey Vero cells by plaque red2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
AID88117Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-2 in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID255146Inhibition of herpes simplex virus type 1 DNA polymerase (95 uL) activity in a solution containing 6.4 mM HEPES (pH 7.5) upon incubation for 12 minutes at 26 degrees C with the compound dissolved in DMSO; [nd = not determined]2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
AID365173Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID291761Cytotoxicity in human C8166 cells2007Bioorganic & medicinal chemistry letters, Aug-15, Volume: 17, Issue:16
Synthesis and biological evaluation of N-acetyl-beta-aryl-1,2-didehydroethylamines as new HIV-1 RT inhibitors in vitro.
AID83039Minimal cytotoxic concentration required to cause a microscopically visible alteration of HEL cell morphology as measured at day 7 postinfection2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID360704Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA/DNAM duplex primed substrate by scintillation proximity assay2007The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11
HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID250798Effect on HSV-2 encephalitis in mice following intraperitoneal dosage at 400 mg/kg; expressed as mean day of death2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID392501Antiviral activity against Human adenovirus 22009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID326137Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID197658Concentration that reduces Rauscher murine leukemia virus titer by 50%1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID412419Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
AID84605Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 2.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID32220Selectivity index expressed as ratio of compound concentration required to reduce the growth of normal uninfected ATH8 cells by 50% to the compound concentration (MIC)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID307436Inhibition of human DNA polymerase gamma by scintillation proximity assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases.
AID360395Inhibition of HIV1 reverse transcriptase p66/p51 mediated single strand incorporation into DNA at +6 position using polypurine tract PPT+6/PPT57 template after 3 mins by gel based assay2007The Journal of biological chemistry, Feb-02, Volume: 282, Issue:5
The pyrophosphate analogue foscarnet traps the pre-translocational state of HIV-1 reverse transcriptase in a Brownian ratchet model of polymerase translocation.
AID235487Selectivity index is the ratio of IC50 to EC50 of F-MuLV.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID393990Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID365175Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID250866Effect on HSV-1 encephalitis in mice following intraperitoneal dosage at 200 mg/kg; expressed as number of survivors/102005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.
AID1811Experimentally measured binding affinity data derived from PDB2004Biochemistry, Nov-02, Volume: 43, Issue:43
Phosphonoformate: a minimal transition state analogue inhibitor of the fosfomycin resistance protein, FosA.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004Biochemistry, Nov-02, Volume: 43, Issue:43
Phosphonoformate: a minimal transition state analogue inhibitor of the fosfomycin resistance protein, FosA.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,581)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990224 (14.17)18.7374
1990's726 (45.92)18.2507
2000's348 (22.01)29.6817
2010's225 (14.23)24.3611
2020's58 (3.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.34 (24.57)
Research Supply Index7.49 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index115.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials116 (6.90%)5.53%
Reviews229 (13.61%)6.00%
Case Studies433 (25.74%)4.05%
Observational4 (0.24%)0.25%
Other900 (53.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring [NCT00947141]Phase 4165 participants (Actual)Interventional2003-02-28Completed
Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function [NCT01199562]153 participants (Actual)Observational2010-12-31Completed
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory [NCT02931539]Phase 3352 participants (Actual)Interventional2016-12-22Completed
A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China [NCT02151240]Phase 494 participants (Actual)Interventional2014-05-31Completed
A Randomised Controlled Phase II Trial of the Adoptive Transfer of Selected Cytomegalovirus-Specific Cytotoxic T Lymphocytes (CMV-CTL) After Allogeneic Stem Cell Transplantation (SCT) in Patients at Risk of CMV Disease [NCT00986557]Phase 278 participants (Anticipated)Interventional2009-09-30Recruiting
Foscarnet-Ganciclovir CMV Retinitis Trial [NCT00000136]Phase 3234 participants (Actual)Interventional1990-03-31Completed
A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy [NCT00000970]Phase 130 participants InterventionalCompleted
Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome [NCT00000726]Phase 153 participants InterventionalCompleted
Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy [NCT00001002]Phase 112 participants InterventionalCompleted
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine [NCT00000985]Phase 326 participants InterventionalCompleted
A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease [NCT00000729]Phase 110 participants InterventionalCompleted
An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies [NCT00002021]0 participants InterventionalCompleted
An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients [NCT00002039]0 participants InterventionalCompleted
Cytomegalovirus Retinitis Retreatment Trial [NCT00000134]Phase 3279 participants (Actual)Interventional1992-12-31Completed
Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component [NCT00000665]240 participants InterventionalCompleted
A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease. [NCT00000856]Phase 10 participants (Actual)InterventionalWithdrawn
A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression [NCT00000697]Phase 20 participants (Actual)InterventionalWithdrawn
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease [NCT00002145]Phase 3145 participants InterventionalCompleted
Foscarnet Treatment of Cytomegalovirus (CMV) Retinitis in AIDS Patients Not Eligible for Ganciclovir Therapy and Ganciclovir Treatment Failures [NCT00002301]0 participants InterventionalActive, not recruiting
CMV Retinitis Retreatment Trial [NCT00000766]Phase 2300 participants InterventionalCompleted
The Effect of Increasing Gastric pH Upon the Bioavailability of Orally Administered Phosphonoformic Acid (Foscarnet) [NCT00000964]Phase 16 participants InterventionalCompleted
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study [NCT00002146]Phase 412 participants InterventionalCompleted
An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies [NCT00002272]0 participants InterventionalCompleted
Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation [NCT03004261]Phase 45 participants (Actual)Interventional2016-11-30Completed
The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment [NCT00002144]Phase 112 participants InterventionalCompleted
An Open Study of Foscarnet Treatment of CMV-Retinitis in AIDS Patients [NCT00002432]0 participants InterventionalCompleted
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure [NCT00000691]Phase 2156 participants InterventionalCompleted
A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) [NCT00002125]Phase 4112 participants InterventionalCompleted
A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis [NCT00001061]Phase 2167 participants InterventionalCompleted
A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1) [NCT03073967]Phase 3153 participants (Anticipated)Interventional2017-05-08Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000134 (1) [back to overview]Morbidity
NCT00000136 (1) [back to overview]Mortality
NCT02931539 (21) [back to overview]Number of Participants With All-cause Mortality by the End of the Study
NCT02931539 (21) [back to overview]Percentage of Participants Receiving Maribavir Rescue Treatment Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control at Week 8 With Maintenance of Effect Through Week 16
NCT02931539 (21) [back to overview]Percentage of Participants Who Achieved Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at End of Week 8 After Starting Maribavir Rescue Treatment
NCT02931539 (21) [back to overview]Percentage of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) (CMV Viremia Clearance) at End of Week 8
NCT02931539 (21) [back to overview]Percentage of Participants Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control at End of Week 8, Followed by Maintenance of Treatment Effect at Week 16
NCT02931539 (21) [back to overview]Percentage of Participants Who Completed 8 Weeks of Study-assigned Treatment With Recurrence of CMV Viremia During the 12 Weeks of Follow-up Period
NCT02931539 (21) [back to overview]Percentage of Participants Who Completed 8 Weeks of Study-assigned Treatment With Recurrence of CMV Viremia During the 20 Weeks of Study
NCT02931539 (21) [back to overview]Percentage of Participants Who Completed 8 Weeks of Study-assigned Treatment With Recurrence of CMV Viremia During the First 8 Weeks of the Treatment
NCT02931539 (21) [back to overview]Percentage of Participants With Recurrence of CMV Viremia at Any Time on Study Regardless of Whether Study-assigned Treatment Was Discontinued Before 8 Weeks of Therapy
NCT02931539 (21) [back to overview]Percentage of Participants With Recurrence of CMV Viremia During the 12 Weeks Follow-up Period Regardless of Whether Study-assigned Treatment Was Discontinued Before 8 Weeks of Therapy
NCT02931539 (21) [back to overview]Percentage of Participants With Recurrence of CMV Viremia During the First 8 Weeks of Study Regardless of Whether Study-assigned Treatment Was Discontinued Before 8 Weeks of Therapy
NCT02931539 (21) [back to overview]Percentage of Participants With Recurrence of CMV Viremia While Off Study-assigned Treatment During Follow-up Period
NCT02931539 (21) [back to overview]Percentage of Participants With Recurrence of CMV Viremia While on Study-assigned Treatment
NCT02931539 (21) [back to overview]Time to All Cause Mortality
NCT02931539 (21) [back to overview]Number of Participants Who Had Maribavir CMV Resistance at Baseline
NCT02931539 (21) [back to overview]Number of Participants Who Had Post-baseline Resistance to Maribavir
NCT02931539 (21) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs During the On-treatment Observation Period
NCT02931539 (21) [back to overview]Percentage of Participants Who Achieved Confirmed CMV Viremia Clearance After Receiving 8 Weeks of Study-assigned Treatment
NCT02931539 (21) [back to overview]Percentage of Participants Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control After Receiving 8 Weeks of Study-assigned Treatment Through Weeks 12, 16 and 20
NCT02931539 (21) [back to overview]Percentage of Participants Who Maintained CMV Viremia Clearance and CMV Infection Symptom Control at the End of Study Week 8 Through Weeks 12 and 20 Regardless of Whether Either Study-assigned Treatment Was Discontinued Before 8 Weeks of Therapy
NCT02931539 (21) [back to overview]Predose Concentration (Cmin) of Maribavir

Morbidity

To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis. (NCT00000134)
Timeframe: Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial

Interventionparticipants (Number)
Intravenous Foscarnet88
Intravenous Ganciclovir93
Combination Therapy93

[back to top]

Mortality

(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.

Interventionparticipants (Number)
Foscarnet107
Ganciclovir127

[back to top]

Number of Participants With All-cause Mortality by the End of the Study

All-cause mortality was analyzed by the end of study regardless of the use of rescue treatment or alternative anti-CMV treatment. Number of participants who died during the entire study period were reported. (NCT02931539)
Timeframe: From enrollment up to end of study (approximately 44 months)

InterventionParticipants (Count of Participants)
Investigator-assigned Anti-CMV Treatment (IAT)13
Maribavir 400 mg27

[back to top]

Percentage of Participants Receiving Maribavir Rescue Treatment Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control at Week 8 With Maintenance of Effect Through Week 16

Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration NCT02931539)
Timeframe: Up to Week 16

Interventionpercentage of participants (Number)
Maribavir Rescue Arm27.3

[back to top]

Percentage of Participants Who Achieved Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at End of Week 8 After Starting Maribavir Rescue Treatment

Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration NCT02931539)
Timeframe: From start of maribavir rescue treatment through 8 weeks

Interventionpercentage of participants (Number)
Maribavir Rescue Arm50.0

[back to top]

Percentage of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) (CMV Viremia Clearance) at End of Week 8

Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration less than (<) lower limit of quantification (LLOQ) that is, <137 International Units per milliliter (IU/mL) when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive postbaseline samples, separated by at least 5 days. Percentage of participants with confirmed CMV viremia clearance at end of study Week 8 regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy, and could not have received alternative anti-CMV treatment were reported. (NCT02931539)
Timeframe: Week 8

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)23.9
Maribavir 400 mg55.7

[back to top]

Percentage of Participants Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control at End of Week 8, Followed by Maintenance of Treatment Effect at Week 16

Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration NCT02931539)
Timeframe: Up to Week 16

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)10.3
Maribavir 400 mg18.7

[back to top]

Percentage of Participants Who Completed 8 Weeks of Study-assigned Treatment With Recurrence of CMV Viremia During the 12 Weeks of Follow-up Period

Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants who completed 8 weeks of study-assigned treatment with recurrence of CMV viremia during the 12 weeks of follow-up period were reported. (NCT02931539)
Timeframe: End of Week 8 up to Week 20 (12 weeks follow-up period)

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)35.5
Maribavir 400 mg40.9

[back to top]

Percentage of Participants Who Completed 8 Weeks of Study-assigned Treatment With Recurrence of CMV Viremia During the 20 Weeks of Study

Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants who completed 8 weeks of study-assigned treatment with recurrence of CMV viremia during the 20 weeks of study were reported. (NCT02931539)
Timeframe: Baseline up to Week 20

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)45.2
Maribavir 400 mg56.1

[back to top]

Percentage of Participants Who Completed 8 Weeks of Study-assigned Treatment With Recurrence of CMV Viremia During the First 8 Weeks of the Treatment

Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia during the first 8 Weeks of the treatment who completed 8 weeks of study-assigned treatment were reported. (NCT02931539)
Timeframe: Baseline up to Week 8

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)9.7
Maribavir 400 mg15.2

[back to top]

Percentage of Participants With Recurrence of CMV Viremia at Any Time on Study Regardless of Whether Study-assigned Treatment Was Discontinued Before 8 Weeks of Therapy

Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during at any time on study regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: Baseline up to Week 20

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)33.8
Maribavir 400 mg56.5

[back to top]

Percentage of Participants With Recurrence of CMV Viremia During the 12 Weeks Follow-up Period Regardless of Whether Study-assigned Treatment Was Discontinued Before 8 Weeks of Therapy

Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during the 12 weeks follow-up period regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: End of Week 8 up to Week 20 (12 weeks follow-up period)

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)21.5
Maribavir 400 mg38.6

[back to top]

Percentage of Participants With Recurrence of CMV Viremia During the First 8 Weeks of Study Regardless of Whether Study-assigned Treatment Was Discontinued Before 8 Weeks of Therapy

Recurrence of CMV viremia was defined as plasma CMV DNA concentration greater than or equal to (>=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance, regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. Percentage of participants with recurrence of CMV viremia during the first 8 weeks of study regardless of whether study-assigned treatment was discontinued before 8 weeks of therapy were reported. (NCT02931539)
Timeframe: At Week 8

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)12.3
Maribavir 400 mg17.9

[back to top]

Percentage of Participants With Recurrence of CMV Viremia While Off Study-assigned Treatment During Follow-up Period

Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia while off study-assigned treatment during follow-up period were reported. (NCT02931539)
Timeframe: Termination of study treatment (Week 8) up to the End of the Study (Week 20)

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)29.2
Maribavir 400 mg40.8

[back to top]

Percentage of Participants With Recurrence of CMV Viremia While on Study-assigned Treatment

Recurrence of CMV viremia was defined as plasma CMV DNA concentration >=LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV test in 2 consecutive plasma samples at least 5 days apart, after achieving confirmed viremia clearance. Percentage of participants with recurrence of CMV viremia while on study-assigned treatment period were reported. (NCT02931539)
Timeframe: Baseline up to termination of study treatment (up to Week 8)

Interventionpercentage of participants (Number)
Investigator-assigned Anti-CMV Treatment (IAT)4.6
Maribavir 400 mg15.8

[back to top]

Time to All Cause Mortality

The time to all-cause mortality by the end of the study participation in days was calculated. Participants who were alive at the last study follow-up (regardless of use of rescue or alternative anti-CMV treatment), withdrew from study or were lost to follow-up were censored at the date of last contact. (NCT02931539)
Timeframe: From enrollment to last serious adverse event (SAE) follow-up (approximately Week 28)

Interventiondays (Median)
Investigator-assigned Anti-CMV Treatment (IAT)73.0
Maribavir 400 mg55.0

[back to top]

Number of Participants Who Had Maribavir CMV Resistance at Baseline

Resistance-associated amino acid substitutions (RASs) to maribavir are known to generally map to the pUL97 and pUL27 genes. Genotyping was performed to identify RASs mapping to the pUL97 and pUL27 genes. Number of participants who had maribavir CMV resistance at baseline were reported. (NCT02931539)
Timeframe: At Baseline

,,
InterventionParticipants (Count of Participants)
RASs associated with pUL97 onlyRASs associated with pUL27 onlyRASs associated with pUL97 and pUL27
Investigator-assigned Anti-CMV Treatment (IAT)300
Maribavir 400 mg010
Maribavir Rescue Arm100

[back to top]

Number of Participants Who Had Post-baseline Resistance to Maribavir

Resistance-associated amino acid substitutions (RASs) to maribavir are known to generally map to the pUL97 and pUL27 genes. Genotyping was performed to identify RASs mapping to the pUL97 and pUL27 genes. Number of participants who had post-baseline resistance to maribavir were reported. (NCT02931539)
Timeframe: After first dose of study drug up to Week 20

,,
InterventionParticipants (Count of Participants)
RASs associated with pUL97 onlyRASs associated with pUL27 onlyRASs associated with pUL97 and pUL27
Investigator-assigned Anti-CMV Treatment (IAT)000
Maribavir 400 mg4500
Maribavir Rescue Arm400

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs During the On-treatment Observation Period

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Serious AE was any untoward medical occurrence (whether considered to be related to study-assigned treatment or not) that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a congenital abnormality/birth defect, or was an important medical event. TEAEs was defined as any adverse events (classified by preferred term) that had a start date on or after the first dose of study treatment or that had a start date before the date of first dose of study treatment, but increased in severity after the first dose of study treatment. (NCT02931539)
Timeframe: Baseline up to 7 days or 21 days (if cidofovir used) after the last dose of study treatment (up to Week 8)

,,
InterventionParticipants (Count of Participants)
TEAEsSerious TEAEs
Investigator-assigned Anti-CMV Treatment (IAT)10643
Maribavir 400 mg22890
Maribavir Rescue Arm2211

[back to top]

Percentage of Participants Who Achieved Confirmed CMV Viremia Clearance After Receiving 8 Weeks of Study-assigned Treatment

Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration NCT02931539)
Timeframe: At Week 8 through Weeks 12, 16 and 20

,
Interventionpercentage of participants (Number)
At Week 8At Week 12At Week 16At Week 20
Investigator-assigned Anti-CMV Treatment (IAT)18.85.15.14.3
Maribavir 400 mg54.922.618.718.3

[back to top]

Percentage of Participants Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control After Receiving 8 Weeks of Study-assigned Treatment Through Weeks 12, 16 and 20

Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration NCT02931539)
Timeframe: At Week 8 through Weeks 12, 16 and 20

,
Interventionpercentage of participants (Number)
At Week 8At Week 12At Week 16At Week 20
Investigator-assigned Anti-CMV Treatment (IAT)18.85.15.14.3
Maribavir 400 mg54.922.618.718.3

[back to top]

Percentage of Participants Who Maintained CMV Viremia Clearance and CMV Infection Symptom Control at the End of Study Week 8 Through Weeks 12 and 20 Regardless of Whether Either Study-assigned Treatment Was Discontinued Before 8 Weeks of Therapy

Confirmed CMV viremia clearance was defined as plasma CMV DNA concentration NCT02931539)
Timeframe: At Week 8 through Weeks 12 and 20

,
Interventionpercentage of participants (Number)
At Week 8At Week 12At Week 20
Investigator-assigned Anti-CMV Treatment (IAT)23.910.39.4
Maribavir 400 mg55.722.618.3

[back to top]

Predose Concentration (Cmin) of Maribavir

Cmin of maribavir was reported. (NCT02931539)
Timeframe: Predose at Week 1, 4 and 8

,
Interventionmicrograms per milliliter (mcg/mL) (Mean)
Cmin at Week 1Cmin at Week 4Cmin at Week 8
Maribavir 400 mg8.777.597.19
Maribavir Rescue Arm8.575.755.65

[back to top]